ClinicalTrials.gg
Not yet recruitingNCT07709910Updated Jul 17, 2026

A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis

A Phase 3 interventional study of Ribupatide Injection and Placebo in Participants With Obesity and Knee Osteoarthritis, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
382
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Planned enrollment
15th of 115
382 · median 100
Started
2026
with 11 others
Phase 3
14 of 136
4 open now
Primary completion
2028-11
later than 31 of 31 live
Registered
130th of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 15th largest by planned enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 31 of the 31 other live ones, and was the 130th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.

03

Conditions studied

  • Participants With Obesity and Knee Osteoarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

1、Voluntarily sign the form, agree to comply with the protocol requirements, and be willing and able to complete the study;

  1. 2、Aged ≥18 years on the date of signing the informed consent form, male or female;
  2. 3、 ≥28.0 kg/m² at screening;
  3. 4、Self-reported dietary and exercise control for 3 months or more prior to screening, and body weight change (difference between maximum and minimum body weight within 3 months) ≤5.0 kg in the 3 months prior to screening;
  4. 5、Based on the American College of Rheumatology criteria, the clinical diagnosis is knee osteoarthritis, and the target knee joint X-ray examination shows a K-L grade of 2-3 at screening.

Exclusion criteria

Exclusion Criteria:

  1. Existence of endocrine diseases that may significantly affect body weight;
  2. Existence of any conditions affecting gastric emptying;
  3. Known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treated gallbladder diseases;
  4. Known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);
  5. Severe infection, major trauma, or major/medium surgery within 1 month prior to screening;
  6. History of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening;
  7. History of in any organ system within 5 years prior to screening;
  8. Existence or suspicion of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illnesses;
  9. Known or suspected history of alcohol and/or drug abuse or addiction;
  10. Symptoms or signs of acute or chronic hepatitis, or any liver disease other than metabolic dysfunction-associated fatty liver disease;
  11. Existence of serious hematologic diseases or any conditions causing hemolysis or red blood cell instability;
  12. Existence of diseases requiring systemic or therapy during the study period;
  13. Known or suspected allergy to GLP-1 and/or GIP receptor agonists or their ;
  14. Participation in any drug or medical device clinical trial within 3 months prior to screening;
  15. Blood donation or cumulative blood loss ≥400 mL within 3 months prior to screening, or receipt of blood transfusion within 3 months;
  16. Participants with mental incompetence or language impairments that prevent full understanding or participation in the trial process.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
382 participants (estimated)

Study arms

  • Experimental
    Ribupatide Injection

    Drug: Ribupatide Injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score after 68 weeks of treatment

    Time frame: after 68 weeks of continuous treatment, assessed every few weeks

  2. Percentage change from baseline in body weight after 68 weeks of treatment

    Time frame: after 68 weeks of continuous treatment, assessed every few weeks

Secondary outcomes

  1. After 68 weeks of treatment, changes from baseline in WOMAC joint function score;

    Time frame: from first dose to 68 weeks after treatment

  2. After 68 weeks of treatment, changes from baseline in WOMAC stiffness score;

    Time frame: from first dose to 68 weeks after treatment

  3. After 68 weeks of treatment, changes from baseline in Average Pain Intensity Numerical Rating Scale (API-NRS);

    Time frame: from first dose to 68 weeks after treatment

  4. After 68 weeks of treatment, changes from baseline in Worst Pain Intensity Numerical Rating Scale (WPI-NRS);

    Time frame: from first dose to 68 weeks after treatment

  5. Use of analgesics during the treatment period;

    Time frame: from first dose up to week 72

  6. After 68 weeks of treatment, changes from baseline in body weight

    Time frame: from first dose to 68 weeks after treatment

  7. After 68 weeks of treatment, changes from baseline in body mass index (BMI)

    Time frame: from first dose to 68 weeks after treatment

  8. After 68 weeks of treatment, changes from baseline in waist circumference

    Time frame: from first dose to 68 weeks after treatment

  9. Adverse events (AE).

    Time frame: from first dose up to week 76

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Nov 2028, 28 months later.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 28 months is above that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 17, 2026
StartEst.
Jul 2026
Primary completionEst.
Nov 2028
CompletionEst.
Dec 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07709910
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Jul 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Yiming Li
Contact
yiming.li@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion